Weekly exenatide controlled blood sugar; Medtronic seeks pump partners;

> A once-weekly formulation of exenatide-controlled blood glucose in Japanese diabetics is in a study sponsored by Amylin (now acquired by Bristol-Myers Squibb [$BMY]) and collaborator Eli Lilly ($LLY). The researchers designed the trial to provide data for submissions in Asia--the previous studies were carried out in non-Asian populations. Article

> Medtronic ($MDT) is seeking pharma partners to pair its pump technology with Alzheimer's disease treatments. Article

> Aegis Therapeutics has been awarded a patent for a fast-acting formulation for triptans for migraine. Press release

> Vivus ($VVUS) has launched Qsymia, a phentermine and topiramate extended-release formulation for weight management. Press release

And Finally… Cuban researchers are developing nanoparticle drugs, including a lower dose version of cyclosporine. Article